X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Aventis Pharma: Margins slide - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Jul 31, 2002

    Aventis Pharma: Margins slide

    Aventis Pharma, has reported a strong topline growth for 1HFY03 on the back of strong performance of its strategic brands and jump in exports to CIS countries. The results for the relevant period under review are on a merged basis with RPR (Rhone Poulenc Rorer) and hence not exactly comparable on a like to like basis.

    (Rs m) 2QFY02 2QFY03 % Change 1HFY02 1HFY03 % Change
    Net Sales 1,212 1,577 30.1% 2,390 2,924 22.3%
    Other Income 13 17 30.8% 55 41 -25.5%
    Expenditure 969 1,317 35.9% 1,956 2,482 26.9%
    Operating Profit (EBDIT) 243 260 7.0% 434 442 1.8%
    Operating Profit Margin (%) 20.0% 16.5%   18.2% 15.1%
    Interest 4 1 -75.0% 11 3 -72.7%
    Depreciation 37 37 0.0% 75 74 -1.3%
    Profit before Tax 215 239 11.2% 403 406 0.7%
    Extraordinary Expenses (VRS) (40) 18 -145.0% 70 1 -98.6%
    Tax 53 87 64.2% 149 130 -12.8%
    Profit after Tax/(Loss) 122 170 39.3% 324 277 -14.5%
    Net profit margin (%) 10.1% 10.8%   13.6% 9.5%  
    No. of Shares (eoy) (m) 23 23   23 23  
    Diluted Earnings per share* 21.2 29.6   28.2 24.1  
    P/E (at current price)   13.0     16.0  
    (*- annualised)            

    Domestic sales have grown 22% from Rs 1.1 bn to Rs 1.3 bn including Rs 84 m from merger of RPR business. The performance has been on the back of strong growth in strategic products such as cardace (42% - cardiovascular), Allegra (24% - allergy), Amaryl (49% - anti-diabetes) and Targocid (40% - anti-infective). Formulations exports sales (mainly to CIS countries) have recorded a growth of more than 68%. However, the management has stated that this exports growth rate is unsustaintable going forward.

    Despite strong sales growth, operating margins have been playing a spoil sport. Operating margins dropped from 18.2% in 1HFY02 to 15.1%. Though the company's products enjoy a strong brand equity, it faces stiff competition from generic products. Raw material consumption to sales ratio indicates a drop in realisations for the company's products. Further, operating margins have also been affected on account of front loading of marketing expenses for products (Lantus and Actonel) expected to be launched in the next year. The company has stated that they expect these product promotion expenses to decline in the coming quarters.

    At the current market price of Rs 385, the stock trades at 12x our expected earnings for FY03. On the back of the support extended by the parent, Aventis has transformed itself from a company catering mainly to the anti-infectives and pain management segments to a company with a strong and focused portfolio of products for the chronic and critical-care therapeutic segments. The strategic brands continue to grow at healthy growth rates and this is expected to offset the impact of the laggards in its folio. This portfolio bias is expected to continue in the foreseeable future as well. Notwithstanding some unclarity on the impact of the DPCO order, valuations of the company are attractive on a peer comparision basis.

     

     

    Equitymaster requests your view! Post a comment on "Aventis Pharma: Margins slide". Click here!

      
     

    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    More Views on News

    Most Popular

    This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

    Aug 17, 2017

    A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

    Dear PM Modi, India is Already Land of Self-Employed, and It Ain't Working(Vivek Kaul's Diary)

    Aug 21, 2017

    Most Indians who cannot find jobs, look at becoming self-employed.

    It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

    Aug 16, 2017

    The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

    5 Steps To Become Financially Independent(Outside View)

    Aug 16, 2017

    Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

    Think Twice Before You Keep Money In A Savings Bank Account(Outside View)

    Aug 22, 2017

    Post demonetisation, a cut in bank savings deposits rates was in the offing.

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    SANOFI INDIA SHARE PRICE


    Aug 23, 2017 (Close)

    TRACK SANOFI INDIA

    • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks

    SANOFI INDIA - FDC LTD. COMPARISON

    Compare Company With Charts

    COMPARE SANOFI INDIA WITH

    MARKET STATS